Endocrine Abstracts

Objectives: Hürthle cell (oncocytic) lesions can be metaplastic or neoplastic events. The neoplastic entities -formerly, oncocytic variant of follicular tumours; Hürthle cell neoplasm (HCN) - include HC adenomas and HC carcinomas and have been recognized as a separate class of tumours by the WHO. The remaining of the thyroid tumours demonstrating “mitochondrion-rich cells” and oncocytic morphology are referred under the umbrella term of “oncocytic vari...

Objectives: Somatic copy number alterations (SCNAs) have been the most common genetic alterations identified in cancer, that frequently related with extensive genomic instability and to an aggressive behavior. Hürthle cell carcinoma is known to be aggressive, having the highest incidence of recurrences, distant metastasis and RAI therapy resistance among all differentiated follicular cell derived thyroid carcinomas. Due to these differences and recent molecular discoverie...

Thyroid cancer therapy is based on surgery followed by radioiodine treatment of tumor remnants and metastases. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS), normally present in thyroid follicular cells’ membrane. We studied the expression of NIS in a series of 229 thyroid primary tumors using real time PCR and immunohistochemistry, and searched for possible associations between NIS expression and clinicopathological feature...

Introduction: Adrenocortical carcinoma (ACC) is a rare entity, usually associated with a poor prognosis. There are still many areas of uncertainty regarding its approach.Methods: A Portuguese ACC register was established in 2020, including information from 24 endocrine centres. Kaplan-Meier was used to calculate overall survival and recurrence; log- rank test to assess survival and progression free survival (PFS) differences between groups; cox-regressio...